$3.28 Billion in Sales Expected for Mylan (MYL) This Quarter

Wall Street analysts expect Mylan (NASDAQ:MYL) to report $3.28 billion in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Mylan’s earnings, with the lowest sales estimate coming in at $3.19 billion and the highest estimate coming in at $3.38 billion. Mylan reported sales of $3.27 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 0.3%. The company is expected to announce its next quarterly earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Mylan will report full-year sales of $3.28 billion for the current year, with estimates ranging from $11.86 billion to $12.05 billion. For the next fiscal year, analysts expect that the company will post sales of $12.65 billion per share, with estimates ranging from $12.30 billion to $13.18 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Mylan.

Mylan (NASDAQ:MYL) last posted its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. Mylan’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.38 earnings per share.

A number of equities research analysts recently commented on MYL shares. TheStreet upgraded Mylan from a “c” rating to a “b-” rating in a research report on Wednesday, January 17th. Guggenheim started coverage on Mylan in a research report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price on the stock. UBS Group set a $46.00 target price on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. Finally, BidaskClub upgraded Mylan from a “hold” rating to a “buy” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. Mylan currently has a consensus rating of “Buy” and a consensus price target of $44.65.

In related news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.69% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. lifted its holdings in Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after buying an additional 1,475 shares during the period. BT Investment Management Ltd purchased a new stake in Mylan during the third quarter worth $142,000. First Personal Financial Services lifted its holdings in shares of Mylan by 77.1% during the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after purchasing an additional 2,106 shares during the last quarter. Mycio Wealth Partners LLC purchased a new stake in shares of Mylan during the 4th quarter valued at $212,000. Finally, Advisor Partners LLC purchased a new stake in shares of Mylan during the 4th quarter valued at $214,000. 75.00% of the stock is currently owned by institutional investors.

Shares of Mylan (NASDAQ MYL) opened at $39.61 on Tuesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The company has a market capitalization of $22,583.97, a PE ratio of 25.05, a P/E/G ratio of 1.14 and a beta of 1.35. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/06/3-28-billion-in-sales-expected-for-mylan-myl-this-quarter.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply